Cystadane (n-bic-d) trial data in an open-label phase Ib/II study showed reduced biomarkers and functional gains in children with aspartylglucosaminuria. Investigators reported significant decreases in urinary glycoasparagines alongside improvements on functional measures, supporting continued development of the oral therapy in a rare lysosomal storage disorder.